7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, July 02 (2024)

Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 7 stocks made the list for top value stocks in the Biotechnology & Medical Research industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.

Why Focus on Undervalued Biotechnology & Medical Research Stocks?

Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.

AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

What Goes Into AAII’s Value Grade?

Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.

Click the button below to learn more about A+ Investor and subscribe today.

7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, July 02 (1)

7 Undervalued Biotechnology & Medical Research Stocks

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 7 undervalued stocks in the Biotechnology & Medical Research industry for Tuesday, July 02, 2024. Let’s take a closer look at their individual scores to see how they measure up against each other and the Biotechnology & Medical Research industry median.

CompanyTickerPrice/SalesPrice/EarningsEV/EBITDAShareholder YieldPrice/Book ValuePrice/Free Cash FlowValue Grade
Adial Pharmaceuticals IncADILnana 0.2 (179.1%) 0.53naB
Bellerophon Therapeutics IncBLPH 0.12nana (28.2%) 0.18naB
Finch Therapeutics Group IncFNCHnana 0.7 (0.1%) 0.11naA
InMed Pharmaceuticals IncINM 0.43na 0.6 (188.8%) 0.22naA
Lenz Therapeutics IncLENZnana 1.5 40.9% 0.42naA
LianBio - ADRLIANYnana 0.6 1.1% 0.16naA
SQZ Biotechnologies CoSQZB 0.09na 0.1 (0.7%) 0.58naA

The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.

The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)

Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).

As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.

Adial Pharmaceuticals Inc’s Value Grade

Value Grade:

MetricScoreADILIndustry Median
Price/Salesnana 6.87
Price/Earningsnana 28.4
EV/EBITDA 0 0.21.6
Shareholder Yield 97 (179.1%)(15.1%)
Price/Book Value 11 0.53 1.79
Price/Free Cash Flownana 24.9

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Adial Pharmaceuticals Inc has a Value Score of 72, which is considered to be undervalued.

Now, let’s assess Adial Pharmaceuticals Inc’s EV/EBITDA ratio, also known as enterprise multiple. At 0.2, when compared to the industry median of 1.6, the company may be considered undervalued in relation to its peers. Value investors could use the enterprise multiple to identify stocks that are considered overvalued or undervalued relative to their industry.

Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. Adial Pharmaceuticals Inc’s shareholder yield is lower than its industry median ratio of

(15.12%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.

As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. Adial Pharmaceuticals Inc’s price-to-book ratio is lower than its industry median ratio of 1.79. This could make Adial Pharmaceuticals Inc more attractive to investors looking for a new addition to their portfolio.

Bellerophon Therapeutics Inc’s Value Grade

Value Grade:

MetricScoreBLPHIndustry Median
Price/Sales 5 0.12 6.87
Price/Earningsnana 28.4
EV/EBITDAnana1.6
Shareholder Yield 87 (28.2%) (15.1%)
Price/Book Value 3 0.181.79
Price/Free Cash Flownana24.9

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Bellerophon Therapeutics Inc has a Value Score of 80, which is considered to be undervalued.

Bellerophon Therapeutics Inc’s price-to-book ratio is higher than its peers. This could make Bellerophon Therapeutics Inc less attractive for value investors when compared to the industry median at 1.79.

You can read more about Bellerophon Therapeutics Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Finch Therapeutics Group Inc’s Value Grade

Value Grade:

MetricScoreFNCHIndustry Median
Price/Salesnana 6.87
Price/Earningsnana 28.4
EV/EBITDA 2 0.71.6
Shareholder Yield 49 (0.1%) (15.1%)
Price/Book Value 2 0.111.79
Price/Free Cash Flownana24.9

Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Finch Therapeutics Group Inc has a Value Score of 97, which is considered to be undervalued.

Finch Therapeutics Group Inc’s price-to-book ratio is higher than its peers. This could make Finch Therapeutics Group Inc less attractive for value investors when compared to the industry median at 1.79.

You can read more about Finch Therapeutics Group Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

InMed Pharmaceuticals Inc’s Value Grade

Value Grade:

MetricScoreINMIndustry Median
Price/Sales 17 0.43 6.87
Price/Earningsnana 28.4
EV/EBITDA 2 0.61.6
Shareholder Yield 97 (188.8%) (15.1%)
Price/Book Value 3 0.221.79
Price/Free Cash Flownana24.9

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

InMed Pharmaceuticals Inc has a Value Score of 83, which is considered to be undervalued.

InMed Pharmaceuticals Inc’s price-to-book ratio is higher than its peers. This could make InMed Pharmaceuticals Inc less attractive for value investors when compared to the industry median at 1.79.

You can read more about InMed Pharmaceuticals Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Lenz Therapeutics Inc’s Value Grade

Value Grade:

MetricScoreLENZIndustry Median
Price/Salesnana 6.87
Price/Earningsnana 28.4
EV/EBITDA 4 1.51.6
Shareholder Yield 2 40.9% (15.1%)
Price/Book Value 8 0.421.79
Price/Free Cash Flownana24.9

LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Lenz Therapeutics Inc has a Value Score of 100, which is considered to be undervalued.

Lenz Therapeutics Inc’s price-to-book ratio is higher than its peers. This could make Lenz Therapeutics Inc less attractive for value investors when compared to the industry median at 1.79.

You can read more about Lenz Therapeutics Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

LianBio - ADR’s Value Grade

Value Grade:

MetricScoreLIANYIndustry Median
Price/Salesnana 6.87
Price/Earningsnana 28.4
EV/EBITDA 2 0.61.6
Shareholder Yield 37 1.1% (15.1%)
Price/Book Value 3 0.161.79
Price/Free Cash Flownana24.9

LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

LianBio - ADR has a Value Score of 98, which is considered to be undervalued.

LianBio - ADR’s price-to-book ratio is higher than its peers. This could make LianBio - ADR less attractive for value investors when compared to the industry median at 1.79.

You can read more about LianBio - ADR’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

SQZ Biotechnologies Co’s Value Grade

Value Grade:

MetricScoreSQZBIndustry Median
Price/Sales 3 0.09 6.87
Price/Earningsnana 28.4
EV/EBITDA 0 0.11.6
Shareholder Yield 56 (0.7%) (15.1%)
Price/Book Value 13 0.581.79
Price/Free Cash Flownana24.9

SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

SQZ Biotechnologies Co has a Value Score of 97, which is considered to be undervalued.

SQZ Biotechnologies Co’s price-to-book ratio is higher than its peers. This could make SQZ Biotechnologies Co less attractive for value investors when compared to the industry median at 1.79.

You can read more about SQZ Biotechnologies Co’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, July 02 (2)

Other Biotechnology & Medical Research Stock Grades

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.

Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Biotechnology & Medical Research stocks as well as other industrys.

Choosing Which of the 7 Best Biotechnology & Medical Research Stocks Is Right for You

Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.

  • Adial Pharmaceuticals Inc stock has a Value Grade of B.
  • Bellerophon Therapeutics Inc stock has a Value Grade of B.
  • Finch Therapeutics Group Inc stock has a Value Grade of A.
  • InMed Pharmaceuticals Inc stock has a Value Grade of A.
  • Lenz Therapeutics Inc stock has a Value Grade of A.
  • LianBio - ADR stock has a Value Grade of A.
  • SQZ Biotechnologies Co stock has a Value Grade of A.

Now that you have a bit more background about each of the 7 undervalued stocks in the Biotechnology & Medical Research industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.

We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.

A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, July 02 (3)

Additional Resources About Biotechnology & Medical Research Stocks

Want to learn more about Biotechnology & Medical Research stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.

  • Why BioCryst Pharmaceuticals Inc’s (BCRX) Stock Is Up 7.93%
  • Why Keros Therapeutics Inc’s (KROS) Stock Is Down 4.22%

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circ*mstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.


7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, July 02 (2024)
Top Articles
Latest Posts
Article information

Author: Maia Crooks Jr

Last Updated:

Views: 6508

Rating: 4.2 / 5 (63 voted)

Reviews: 86% of readers found this page helpful

Author information

Name: Maia Crooks Jr

Birthday: 1997-09-21

Address: 93119 Joseph Street, Peggyfurt, NC 11582

Phone: +2983088926881

Job: Principal Design Liaison

Hobby: Web surfing, Skiing, role-playing games, Sketching, Polo, Sewing, Genealogy

Introduction: My name is Maia Crooks Jr, I am a homely, joyous, shiny, successful, hilarious, thoughtful, joyous person who loves writing and wants to share my knowledge and understanding with you.